Karina Tschon

Karina Tschon

Managing Associate
MLaw, Avocate




Téléphone direct: +41 58 658 14 39

Curriculum Vitae

PDF download

Karina Tschon works as an Attorney at Law at Walder Wyss. She advises clients on matters of commercial and corporate law.

Born in 1990, Karina Tschon studied at the University of Basel (BLaw 2014, MLaw 2016). Prior to joining Walder Wyss as an Attorney at Law, she worked as a trainee lawyer at the Civil District Court Basel-Landschaft East, the Criminal Court of Basel-Stadt, in a law firm in Basel and in the legal department of a pharmaceutical company in Basel. Karina Tschon was admitted to the bar in 2019 in the canton of Basel-Stadt.

Karina Tschon's professional languages are German and English.

SixPeaks Bio AG debuts with USD 110 million in Funding

Promotions at Walder Wyss

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Pierre Fabre Laboratories acquires Vertical Bio AG

Alentis Therapeutics Closes USD 105m Series C Funding

Group of investors acquires iPet.ch GmbH

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

Versant Ventures launches Vector BioPharma with USD 30m Series A

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

Astorg acquires CordenPharma from ICIG

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky secures financing in the amount of EUR 6 million

Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension

Alloy Therapeutics acquires deepCDR Biologics

GlycoEra CHF 45m Series A Financing

Perconex Holding GmbH acquires Flex Suisse AG

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

Alentis Therapeutics lève USD 67 millions dans le cadre d’un financement de série B

proLogistik Holding GmbH acquiert XELOG AG

Calibre Scientific, Inc. acquires HUBERLAB.AG

Boehringer Ingelheim rachète NBE-Therapeutics pour 1,18 milliard d’euros

Financement de série A de CHF 54 millions de Noema Pharma

Synendos Therapeutics CHF 20m Series A Financing

VectivBio USD 110m Crossover Financing

Financement de série B de 96 millions USD de Monte Rosa Therapeutics

Tour de table série B de 19 millions CHF de BioVersys

Versant Ventures lance Matterhorn Biosciences

Versant Ventures lance Bright Peak Therapeutics

Walder Wyss conseille BC Plateforms sur le financement de série C à hauteur de 15 millions USD et sur un partenariat avec IQVIA visant à l’extension de l’analyse de données génomiques